GAP Index Calculator
Compute the GAP score for idiopathic pulmonary fibrosis using gender, age, forced vital capacity (FVC) percentage predicted, and diffusing capacity (DLCO) percentage predicted. Get validated Stage I, II, or III disease classification with 1-year, 2-year, and 3-year mortality risk estimates based on the Ley et al. 2012 GAP model and ATS/ERS/JRS clinical guidelines.
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions.
Patient Variables
Results
| Variable | Patient Value | Points Scored | Maximum Points | % of Max Used |
|---|---|---|---|---|
| GAP Total Score | — | 0 | 8 | 0% |
| GAP Stage | Score Range | 1-Year Mortality | 2-Year Mortality | 3-Year Mortality |
|---|
| GAP Stage | Transplant Recommendation | Urgency | Key Action |
|---|
- Monitoring frequency: Every 3-6 months with spirometry and DLCO
- Antifibrotic therapy: Initiate pirfenidone or nintedanib if not already started
- Lung transplant: Assess baseline eligibility; formal referral if FVC approaching 80%
- Oxygen therapy: Prescribe supplemental oxygen if resting or exertional desaturation present
- Pulmonary rehabilitation: Refer to structured pulmonary rehabilitation programme
- Goals of care: Introduce advance care planning at early stage in accessible language
- Comorbidity review: Screen for pulmonary hypertension, gastro-oesophageal reflux, sleep apnoea
- Monitoring frequency: Every 3 months; consider 6-minute walk test at each visit
- Antifibrotic therapy: Strongly indicated; optimise dosing and adherence
- Lung transplant: Urgent referral to transplant centre if not already under evaluation
- Pulmonary hypertension: Formal right heart catheterisation if clinically suspected
- Advance care planning: Formal goals of care discussion recommended
- Palliative care: Consider early integration for symptom management (dyspnoea, cough, anxiety)
- Acute exacerbation preparedness: Discuss management plan for acute deterioration
- Monitoring frequency: Monthly clinical review; frequent spirometry and oxygenation monitoring
- Antifibrotic therapy: Confirm in place; consider safety of continuing in very advanced disease
- Lung transplant: Expedite listing assessment; contact transplant centre urgently if not listed
- Palliative care: Early integration strongly recommended; concurrent with active management
- Oxygen therapy: High-flow or ambulatory oxygen as clinically required
- Advance care planning: Comprehensive advance care plan including resuscitation preferences
- End-of-life planning: Discuss preferred place of care and end-of-life preferences with patient and family
| Monitoring Parameter | Stage I Frequency | Stage II Frequency | Stage III Frequency |
|---|---|---|---|
| Spirometry (FVC) | Every 3-6 months | Every 3 months | Every 1-2 months |
| DLCO | Every 6 months | Every 3-6 months | Every 3 months |
| 6-Minute Walk Test | Every 6 months | Every 3 months | As tolerated |
| GAP Score Recalculation | Each PFT visit | Each PFT visit | Each PFT visit |
| Chest HRCT | Annually or if change | If clinical change | If management impact |
| Echocardiography | If PH suspected | Annually or if change | As clinically indicated |
| Transplant Assessment | Baseline eligibility | Urgent referral | Expedite listing |
This calculator is provided for informational and educational purposes only. It is not intended to replace professional medical advice, diagnosis, or treatment. Always consult with a qualified healthcare professional before making any medical decisions. The results from this calculator should be used as a reference guide only and not as the sole basis for clinical decisions. Mortality estimates are derived from population-level cohort data and individual patient outcomes may vary substantially.
About This GAP Index Calculator for Idiopathic Pulmonary Fibrosis
This GAP Index calculator is designed for pulmonologists, respiratory physicians, multidisciplinary team members, and healthcare professionals managing patients with idiopathic pulmonary fibrosis. It computes the validated GAP score from four clinical variables routinely captured during pulmonary function testing and clinical assessment, producing a total score from 0 to 8 that maps onto three prognostic disease stages.
The calculator implements the Ley et al. 2012 GAP model, assigning points for biological sex (0-1 points), patient age bracket (0-2 points), forced vital capacity percentage predicted (0-2 points), and diffusing capacity for carbon monoxide percentage predicted (0-3 points). The results section includes a gradient zone bar chart showing score position across risk zones. The full-width risk ladder displays the active score across all nine possible GAP values. Four data-rich tabs provide score breakdown, mortality comparisons across all stages, transplant threshold assessment, and a clinical management guide.
Mortality risk estimates at 1 year, 2 years, and 3 years are drawn from the original GAP validation cohort. Stage I (scores 0-3) indicates low risk; Stage II (scores 4-5) indicates intermediate risk requiring expedited transplant evaluation; Stage III (scores 6-8) indicates high risk warranting urgent clinical review and palliative care integration. All results should be interpreted by a qualified healthcare professional within the full clinical context of the individual patient.
GAP Index Calculator: Understanding Gender Age Physiology Score for Idiopathic Pulmonary Fibrosis Prognosis
Idiopathic pulmonary fibrosis (IPF) is a progressive, fibrosing interstitial lung disease associated with significant morbidity and mortality. Predicting disease progression and survival in IPF has historically been challenging due to the heterogeneous nature of the condition. The GAP Index — standing for Gender, Age, and Physiology — was developed to provide clinicians with a validated, simple scoring tool to stage disease severity and estimate mortality risk in patients with IPF.
The GAP model was first described by Ley and colleagues in 2012 and has since become one of the most widely referenced clinical staging systems in IPF management. Unlike complex imaging-based tools or invasive biomarkers, the GAP Index relies entirely on clinical variables routinely available in outpatient pulmonary practice: patient sex, age, and two physiological lung function measurements — forced vital capacity (FVC) and diffusing capacity of the lung for carbon monoxide (DLCO).
This calculator provides clinicians, researchers, and patients with an accessible tool to compute the GAP score, determine GAP stage (I, II, or III), and interpret the associated 1-year, 2-year, and 3-year mortality risk estimates. All results should be interpreted in the clinical context of the individual patient and in conjunction with multidisciplinary team assessment.
Age: ≤60 years = 0 pts | 61-65 years = 1 pt | >65 years = 2 pts
FVC % predicted: >75% = 0 pts | 50-75% = 1 pt | <50% = 2 pts
DLCO % predicted: >55% = 0 pts | 36-55% = 1 pt | ≤35% = 2 pts | Cannot perform = 3 pts
Total Range: 0-8 points
Background and Development of the GAP Index
The GAP Index was developed and validated using data from two large IPF cohorts at academic medical centres. In the original derivation study, Ley and colleagues identified that three clinical domains — gender, age, and pulmonary physiology — were independent predictors of mortality in IPF. By combining these variables into a composite score, the investigators created a staging system that stratified patients into three meaningful prognostic groups with distinct survival trajectories.
The original derivation cohort included 228 patients with IPF, and external validation was performed in a separate cohort of 330 patients. Both analyses confirmed the GAP score's ability to discriminate between patients at low, intermediate, and high risk of death at 1, 2, and 3 years. The model has subsequently been validated in numerous independent cohorts worldwide, supporting its generalisability across diverse patient populations.
A key strength of the GAP model is its simplicity. Unlike risk scores requiring six-minute walk test distance, high-resolution CT imaging scores, or complex biomarker panels, the GAP Index requires only four data points routinely captured during initial pulmonary function testing and clinical assessment. This accessibility makes it applicable in community pulmonary practices, resource-limited settings, and telemedicine contexts.
Understanding GAP Staging: Stage I, II, and III
The GAP score of 0 to 8 maps onto three disease stages, each with progressively worse prognosis:
Stage II (Intermediate Risk): 1-year mortality approximately 16.2%; 2-year ~29.9%; 3-year ~42.1%
Stage III (High Risk): 1-year mortality approximately 39.2%; 2-year ~62.1%; 3-year ~76.8%
These mortality estimates represent population-level probabilities derived from the original validation cohort. Individual patient outcomes may differ substantially based on comorbidities, acute exacerbations, response to antifibrotic therapy, and access to lung transplantation. Clinicians should use these estimates as one component of a comprehensive prognostic discussion, not as deterministic predictions.
Gender as a Prognostic Variable in IPF
The inclusion of gender in the GAP Index reflects well-established epidemiological observations that male sex is associated with worse outcomes in IPF. Men account for approximately 65-70% of IPF diagnoses globally and have consistently demonstrated shorter survival times compared to women with equivalent physiological impairment. The precise mechanisms underlying this sex-based difference remain incompletely understood.
Proposed explanations include differences in occupational and environmental exposures, hormonal influences on lung fibrosis pathways, smoking history patterns, and potential differences in immune regulation between sexes. Some studies suggest that oestrogen may have antifibrotic effects, potentially explaining relatively preserved survival in women with IPF. Additionally, women with IPF have historically been more likely to have concurrent features of connective tissue disease, which may represent a distinct and less aggressive fibrotic phenotype.
The GAP model assigns 1 point for male sex and 0 points for female sex, contributing up to 12.5% of the maximum possible score. When interpreting individual GAP scores, clinicians should note that the gender variable alone does not determine clinical management but contextualises physiological data within the established epidemiology of the disease.
Age and Disease Progression in Idiopathic Pulmonary Fibrosis
Age is the strongest individual risk factor for IPF diagnosis and progression. The disease predominantly affects individuals over 60 years of age, with median age at diagnosis in most registry data ranging from 65 to 70 years. Older age confers both a higher burden of comorbidities — cardiovascular disease, diabetes, pulmonary hypertension — and potentially altered lung regenerative capacity that may accelerate fibrotic progression.
The GAP scoring system uses two age thresholds. Patients aged 60 years or younger receive 0 points; those aged 61-65 receive 1 point; and those over 65 years receive 2 points. This graduated approach reflects the non-linear relationship between age and mortality risk in IPF. A 55-year-old with IPF, while still facing a serious diagnosis, has meaningfully different survival prospects than a 72-year-old with identical pulmonary physiology.
From a practical standpoint, age also influences treatment decisions. Younger patients with GAP Stage II or III disease are more likely to be considered candidates for lung transplant evaluation, and initiating this process early — while performance status remains adequate — is a critical clinical priority. The GAP score can serve as a prompt for transplant referral discussions when scores indicate intermediate or high-risk staging.
Forced Vital Capacity (FVC) in the GAP Index
Forced vital capacity, expressed as a percentage of the age-, sex-, and height-predicted value, is one of the two physiological anchors of the GAP Index. FVC reflects the total volume of air that can be forcefully exhaled after full inhalation and serves as a reliable measure of the restrictive ventilatory defect characteristic of IPF. A decline in FVC over time is the most commonly used endpoint in clinical trials of antifibrotic agents.
In cross-sectional assessment, FVC above 75% predicted earns 0 GAP points; FVC between 50% and 75% earns 1 point; and FVC below 50% earns 2 points. The 75% threshold represents mild impairment, the 50% threshold moderate-to-severe impairment. IPF guidelines from multiple professional societies recommend regular FVC monitoring — typically every 3 to 6 months — to detect progression early and guide treatment escalation or transplant listing.
A relative decline in FVC of 10% or more over 12 months has been associated with significantly increased mortality in IPF. Even smaller declines of 5-10% carry prognostic significance. The GAP Index uses absolute FVC percentage at a single time point rather than longitudinal change, making it a cross-sectional staging tool rather than a progression monitoring tool.
Diffusing Capacity for Carbon Monoxide (DLCO) in the GAP Index
Diffusing capacity for carbon monoxide, or DLCO, measures the lung's ability to transfer gas from alveolar air into pulmonary capillary blood. In IPF, fibrotic remodelling disrupts the alveolar-capillary interface, reducing gas exchange efficiency. DLCO is often the earliest physiological parameter to decline in IPF, sometimes falling below normal limits before restrictive changes are detectable on spirometry.
The GAP scoring system assigns DLCO the greatest weighting of any individual variable, with a maximum of 3 points compared to 2 points for all other variables. This reflects the strong prognostic significance of DLCO impairment in IPF. Patients with DLCO above 55% predicted receive 0 points; those with DLCO between 36% and 55% receive 1 point; DLCO at or below 35% receives 2 points; and patients unable to perform a valid DLCO measurement receive 3 points automatically.
The "cannot perform" category for DLCO typically captures patients with severe dyspnea, inability to sustain breath-hold for the required 10 seconds, or technical limitations. This group is assigned the maximum DLCO points because inability to perform the manoeuvre generally correlates with very advanced physiological impairment, reflecting the worst physiological stratum.
Interpreting GAP Score in Clinical Practice
The GAP score is best understood as a cross-sectional snapshot of prognosis rather than a comprehensive clinical assessment tool. It quantifies the mortality risk associated with a specific combination of clinical characteristics at a given time point. As disease progresses and physiology declines, GAP scores and stages will change, typically worsening over time.
In practice, clinicians might use the GAP Index to:
- Counsel patients on prognosis at the time of diagnosis or during follow-up assessments
- Identify patients at high risk who should be prioritised for urgent specialist review or transplant evaluation
- Guide discussions about goals of care and advance care planning, particularly for GAP Stage III patients
- Contextualise antifibrotic therapy decisions, with higher-stage patients potentially deriving greater urgency benefit from treatment initiation
- Stratify patients in clinical research and registry settings
It is important to note that the GAP Index does not incorporate several clinically relevant factors, including acute exacerbations, comorbidities (particularly pulmonary hypertension, lung cancer, and emphysema), biomarkers such as MUC5B genotype or telomere length, and high-resolution CT features beyond physiological correlates. Patients with identical GAP scores may have substantially different clinical trajectories depending on these additional factors.
Comparison with Other IPF Prognostic Tools
Several other prognostic models have been developed for IPF. The ILD-GAP model extends the GAP framework to include other fibrotic interstitial lung diseases. The du Bois risk score incorporates hospitalisation history, six-minute walk test distance, and physiological variables to predict 1-year mortality. The CALIPER score uses quantitative CT analysis to derive a computational index of fibrosis extent. Each model has specific applications and validated contexts.
Among these tools, the original GAP Index remains the most widely implemented due to its simplicity and the universal availability of its input variables. The NICE guidelines in the United Kingdom, guidelines from the American Thoracic Society (ATS), European Respiratory Society (ERS), and the Japanese Respiratory Society (JRS) reference the GAP model in IPF management frameworks.
While the du Bois model may offer slightly better discrimination in some datasets — particularly when six-minute walk test data are available — the GAP Index performs comparably in most validation studies and has the advantage of requiring only standard spirometry and DLCO without exercise testing. In settings where walk testing is unavailable or unsafe, the GAP Index is the preferred staging tool.
Limitations of the GAP Index
Despite its clinical utility, the GAP Index has several important limitations that users should understand. First, it was developed primarily in academic North American cohorts and may not perfectly capture prognosis in all ethnic populations or healthcare settings. Some studies in East Asian populations have noted modest calibration differences, though discrimination has generally remained acceptable.
Second, the GAP model does not incorporate disease trajectory information. Two patients with identical GAP scores — one clinically stable for three years and one who has declined rapidly over six months — face very different near-term mortality risks. Longitudinal physiological data, particularly serial FVC measurements, should complement cross-sectional GAP staging.
Third, the GAP Index does not account for antifibrotic therapy use, which has changed the natural history of IPF since the model's development in the era before pirfenidone and nintedanib were widely available. Whether GAP-derived mortality estimates remain accurate in patients on antifibrotic therapy is an active area of investigation, with some evidence suggesting that antifibrotic treatment may attenuate the mortality risk associated with higher GAP stages.
Fourth, DLCO measurement quality is subject to significant variability between laboratories and testing sessions. Poor quality DLCO manoeuvres — with inadequate breath-hold, air leaks, or excessive haemoglobin values — may produce unreliable percentage predicted values, affecting GAP scoring accuracy. Clinicians should verify that DLCO measurements used for GAP calculation meet acceptability criteria.
GAP Index and Lung Transplant Referral
Lung transplantation remains the only intervention associated with improved survival in IPF. International guidelines recommend that all patients with IPF be evaluated for transplant eligibility early in the disease course. Specific physiological thresholds that trigger urgent transplant listing include FVC below 80% predicted, DLCO below 40% predicted, or significant decline in FVC or DLCO over 6-12 months.
GAP Stage II and Stage III scores align closely with these thresholds. A patient with GAP Stage II or III typically has physiological values that should prompt immediate transplant referral if not already initiated. The International Society for Heart and Lung Transplantation (ISHLT) guidelines and many national transplant frameworks recognise the GAP Index as one tool to support listing urgency decisions, alongside direct physiological measurements and functional capacity assessment.
In many countries, lung transplant allocation is governed by composite scoring systems (such as the Lung Allocation Score in the United States) that incorporate disease severity directly from physiological measurements rather than GAP stage. Nevertheless, the GAP score provides a clinically intuitive communication tool for explaining prognosis to patients and families when discussing transplant options.
The Role of Antifibrotic Therapy and GAP Staging
Two antifibrotic medications — pirfenidone and nintedanib — are approved for the treatment of IPF in most countries worldwide. Both agents have been shown in phase III randomised controlled trials to reduce the annual rate of FVC decline by approximately 50% compared to placebo, though neither agent reverses established fibrosis or improves gas exchange. Their approval has shifted the landscape of IPF management since 2014.
Current guidelines from the ATS, ERS, JRS, and Latin American Thoracic Association (ALAT) conditionally recommend antifibrotic therapy for all patients with IPF, regardless of baseline GAP stage. However, in clinical practice, GAP staging can support discussions about treatment urgency. Higher-stage patients with more rapid physiological decline may have less time to defer treatment initiation, and shared decision-making conversations may be shaped by prognostic information from the GAP score.
Serial GAP Assessment and Disease Monitoring
Because pulmonary function testing is routinely performed at 3-6 month intervals in IPF management, the GAP score can be recalculated at each visit to track disease progression. An increase in GAP score over time — even within the same stage — may reflect subclinical deterioration that should prompt clinical reassessment. Movement between GAP stages, particularly from Stage I to Stage II or from Stage II to Stage III, should trigger urgent review of treatment strategy, transplant listing status, and goals of care.
Longitudinal GAP tracking also has research utility. In clinical trials and registries, serial GAP scores can serve as an accessible composite outcome measure, capturing overall disease burden across multiple physiological domains in a single numeric index. This approach may complement primary endpoints such as FVC decline or event-based endpoints such as acute exacerbation or death.
Application of the GAP Index Across Diverse Populations
The GAP Index was validated primarily in North American and European cohorts of predominantly white patients with IPF. Its performance in other ethnic populations has been examined in several studies. A validation study in Japanese patients with IPF found that the GAP model retained acceptable discrimination, though some calibration differences were noted, possibly reflecting distinct IPF phenotypes in East Asian populations.
Studies in South Asian, South American, and African patient populations are more limited. The Global Registry of Pulmonary Fibrosis (GRPF) and similar international registries are generating data that may allow refinement of GAP estimates for diverse populations. In the interim, clinicians applying the GAP Index to patients from populations not well-represented in the original validation cohorts should interpret mortality estimates with appropriate caution and supplement GAP staging with local registry data where available.
Genetic risk factors for IPF — including the MUC5B promoter variant rs35705950 — vary in frequency across ethnic populations, with higher prevalence in European-ancestry individuals. Environmental exposures, access to diagnostic resources, and healthcare utilisation patterns also differ globally. These factors may influence both the prevalence and the clinical trajectory of IPF in ways that GAP-derived mortality estimates do not fully capture.
Patient Communication Using the GAP Index
The GAP Index can be a valuable communication tool during prognostic discussions with patients and families. Converting a numerical score into a stage — and associating that stage with approximate probability estimates — provides a structured framework for difficult conversations. However, the manner in which prognostic information is communicated matters as much as the information itself.
Clinicians should present GAP-derived estimates as probability ranges rather than certainties, acknowledge the uncertainty inherent in population-level predictions applied to individuals, frame the discussion within the context of treatment options and supportive care planning, and ensure patients have adequate time and support to process prognostic information. Shared decision-making tools and patient-facing educational materials that incorporate GAP staging are available from several patient advocacy organisations, including the Pulmonary Fibrosis Foundation and Action for Pulmonary Fibrosis.
GAP Index in the Context of IPF Multidisciplinary Care
The diagnosis and management of IPF is increasingly delivered through multidisciplinary teams (MDTs) comprising pulmonologists, radiologists, pathologists, respiratory physiotherapists, palliative care specialists, and lung transplant programmes. The GAP score serves as a common language within these teams — a shorthand for disease severity that contextualises both acute clinical decisions and long-term management planning.
At MDT meetings, presenting a patient's GAP stage alongside their current treatment status, hospitalisation history, and functional capacity provides a comprehensive prognostic picture. MDTs can use this information to prioritise transplant referrals, coordinate palliative care involvement, and ensure that patients at highest risk — GAP Stage III — are receiving the full complement of supportive interventions.
Frequently Asked Questions
Conclusion
The GAP Index remains the most widely validated and clinically implemented staging system for idiopathic pulmonary fibrosis. Its elegance lies in its simplicity — four variables routinely available in any pulmonary function laboratory combine to produce a score with meaningful prognostic differentiation across three disease stages. For clinicians managing patients with IPF, the GAP Index provides a standardised framework for prognostic communication, treatment urgency assessment, and transplant referral decisions. For patients, it offers a way to contextualise their physiological test results within an evidence-based prognostic framework.
While the GAP Index has important limitations — particularly its lack of longitudinal trajectory information and its development in pre-antifibrotic therapy cohorts — these do not diminish its clinical utility as a cross-sectional staging tool. Used alongside serial FVC monitoring, multidisciplinary team review, and individualised clinical assessment, the GAP Index contributes meaningfully to evidence-based IPF care.
This calculator is provided for educational and informational purposes only. Clinical decisions regarding IPF management should be made by qualified healthcare professionals with expertise in interstitial lung disease, incorporating the full clinical picture of the individual patient.